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creativecommons.org/licenses/by-nc-nd/4.0/).The combined transplantation of a thoracic organ and the liver is
performed in patients with dual-organ failure in whom survival is
not expected with single-organ transplantation alone. Although
uncommonly performed, the number of combined liver-lung and
liver-heart transplants is increasing. Anesthetic management of
this complex procedure is challenging. Major blood loss, prolonged
operation time, difficult weaning of cardiopulmonary bypass and
coagulation disturbances are common. Despite the complexity of
surgery, the outcome is comparable to single-organ transplant.
© 2020 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Transplantation of the liver combined with a thoracic organ (cLiThTx) is a life-saving intervention
for patients with dual-organ failure who are unlikely to survive the transplantation of a single organ.
This complex procedure is increasingly performed as the number of patients on the waiting list isesiology, University Medical Center Groningen, University of Goningen,
.
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ier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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is challenging. This review provides an overview of anesthetic management of cLiThTx.
Background
The first successful combined liver-heart transplantation (cLiHTx) was performed in 1984 on a 6-
year-old girl with severe heart disease secondary to familial hypercholesterolemia [2,3]. The donated
liver and heart were from the same donor and were transplanted on cardiopulmonary bypass (CPB)
during a 15-h procedure. They startedwith the heart, and once function of the new heart was sufficient,
the new liver was transplanted with the patient still on CPB. She was discharged from the hospital in
good clinical condition 28 days after surgery. Unfortunately, two unsuccessful cases around this time
were also reported. Major factor contributing to the fatal outcome of both cases was a size mismatch
between donor and recipient [3]. From 1984 to 2000, only 12 cases of cLiHTx are reported [4]. However,
over the last decade the number of combined cLiHTx is growing fast. The Organ Procurement and
Transplantation Network reports a total number of 312 cLiHTx in the United States since 1992 [5]. For
Europe, Eurotransplant report the first cLiHTx in 2010, with a total of 11 cLiHTx up to this date [6]. In the
United States, experience with combined liver-lung transplantation (cLiLuTx) is even more limited.
Between 1994 and 2016 only 84 cLiLuTxwere performed. For Europe, the number of reported cLiLuTx is
higher than the number of cLiHTx. Since 2009, Eurotranplant reports 114 cases of cLiLuTx.
Population
Advanced heart disease in liver transplant candidates or severe liver disease in heart transplant
candidates are indications for cLiHTx. Likewise, advanced pulmonary disease in liver transplant can-
didates or severe liver disease in liver transplant candidates are indications for cLiLuTx. In the majority
of cases, the cardiac or pulmonary indication for transplantation carries more weight than the liver
indication. For instance, in a case with amyloidosis with restrictive cardiomyopathy, the liver is
structurally normal but is transplanted to treat the underlying metabolic condition. Therefore, in
cLiThTx Model for End-stage Liver Disease (MELD) scores are significantly lower compared to single-
organ liver transplant.
The largest cohort of cLiHTx (n¼ 97) is described by Cannon et al. [7]. Themost common indications
for cardiac transplantation were amyloidosis (27%), congenital cardiac disease (18%), and idiopathic
dilated cardiomyopathy (14%). For the liver, the most common indications for transplantation were
amyloidosis (28%), cardiac cirrhosis (18%), and chronic hepatitis C (12%). Of the recipients, 70% was
male, with a mean ± SD age of 44 ± 16. Cardiac output at registration was 4.5 ± 1.6 L/min, with 25% of
the patients on inotropic support and 4% had a ventricular assist device.
Over the last decade, cLiHTx is increasingly performed inpatientswith severe congenital heart disease
(CHD). Improvedmedical care increased thenumberof livingadultswithCHD.Adultpatientswitha failing
Fontan circulation are known to develop advanced liver disease [8]. In CHD, cardiac cirrhosis is the most
commonhepatic indication for cLiHTx [9]. Compared to patientswithout CHD, transplanted patientswith
CHD are significantly youngerwith a lower Pulmonary Artery (PA)wedge pressure and PAmeanpressure
[10,9]. MELD scores and other parameters of liver function are comparable [10].
For cLiLuTx pulmonary indications are Cystic Fibrosis and a1-antitrypsin deficiency accompanied by
cirrhosis. Indications with end-stage liver disease with pulmonary compromise are portopulmonary
hypertension and hypoxia caused by intrapulmonary shunting [11,12]. Cystic Fibrosis is by far the most
common indication for cLiLuTx. Around 10% of patients with cystic fibrosis develop cirrhosis, and it is
the second cause of death in these patients. For both cLiHTx and cLiLuTx, there are no clear criteria for
listing, so guidelines for listing vary by institution.
Preoperative
The decision to perform a combined transplantation results from the fact that the individual
organs are too sick to support the effects of a sequential transplantation strategy: the cirrhotic liver
does not tolerate a CPB procedure well and patients with end stage liver disease in need of a lung or
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thetic evaluation is mandatory. Preoperative evaluation essentially consists of screening of the
functional status of the individual organs to be transplanted. A full screening list consists of (but is
not limited to):
 Cardiopulmonary exercise testing
 Cancer/malignancy screening
 Evaluation of end organ effects of chronic disease
 Pulmonary function testing
 Hemodynamic evaluation by cardiac catheterization
 Liver biopsy
 INR and metabolic panel to calculate the MELD score
 Thrombocyte count (portal hypertension-related thrombocytopenia)
 Serologic workup for underlying liver diseases (viral or other)
 Abdominal imaging: spleen size, liver nodules or masses, and ascites
A multidisciplinary approach to patients undergoing organ transplantation has proven its benefits
over years. In that sense, the pre- per- and postoperative approach of single-organ transplantations has
become more or less a routine in transplant centers around the world.
However, it would be unwise to copy paste this approach to combined transplantations. It is our
conviction that the preoperative approach should be two folded: at the transplant listing meeting, test
results and possible perioperative issues should be discussed (difficulty of resection, ascites, and
vascular access). As the team discussing the patient at the listing meeting is possibly not the team
actually performing the transplantation procedure, a second meeting, hours in advance of the pro-
cedure, with the actual transplantation team, is of inestimable value. The team can discuss the actual
status of the patient, vascular access, plan for emergency cannulation, back-up plan, and management
of coagulopathy, and estimate the time needed for anesthesia preparation and surgical dissection prior
to organ arrivals. The introduction of new machine organ perfusion techniques can help to facilitate
this phase of the procedure. Machine perfusion is revolutionizing in the field of liver transplantation
and is undergoing rapid clinical implementation [13]. First clinical experiences suggest that machine
perfusion results in superior outcome, compared to the transplantation of static cold storage-only
preserved human livers [14,15]. Ex situ machine perfusion strategies allow among others recon-
ditioning of livers prior to transplantation, rather than standard cold storage alone. Oxygenated ma-
chine perfusion could restore mitochondrial function and increase endothelial function and integrity,
thereby alleviating the inflammatory response upon reperfusion.Intraoperative
Surgical considerations
A cLiThTx is performed under the same operative setting. As the acceptable cold ischemic time for
lungs and hearts is shorter than for the liver, traditionally the heart or lungs are transplanted prior to
the liver. Also, a severely insufficient heart is unlikely to tolerate the hemodynamic changes during
transplantation of the liver. In the earliest cLiHTx cases, dissection of the abdomen and chest was
performed before arrival of the organs. Both the heart and liver transplants were performed on CPB
under full heparinization [2,3]. The liver is done with a piggyback or standard bi-caval technique, with
or without veno-venous bypass. For the heart, the bi-caval implantation technique is most often used
(70%) [9]. The alternative is the traditional bi-atrial technique. In pediatric cases, the “en-bloc” tech-
nique is an alternative in which both the heart and liver are simultaneously implanted on CPB and
thereafter simultaneously reperfused [16]. With the growing experience with organ perfusion, the
possibility arises to transplant the liver prior in selected patients. The “liver-first” technique was
described by Ceulemans et al. who did their first “liver-first” case in a 62-year-old patient with end-
stage chronic obstructive pulmonary disease who developed drug-induced acute liver failure during
her workup for a bilateral lung transplant [17,18]. The only life-saving therapeutic option was to
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liver graft and bilateral lung grafts became available for transplantation. Severe bleeding was antici-
pated in the recipient because of liver failure-induced severe coagulation disorder, so the decision was
made to transplant the liver first while the lungs were on normothermic perfusion and oxygenation
[17,18]. Although the liver-first technique is increasingly performed, the standard procedure remains to
transplant the lungs prior to the liver. In most cases of cLiLuTx, both lungs are transplanted. The
commonly described technique is to transplant the lungs with or without the use of CPB and leaving
the chest open prior to liver transplant. An alternative is to close the chest prior to liver transplant to
prevent contamination [19]. Some cases describe that the abdominal dissection is performed prior to
transplanting the lungs or heart. In case of cLiHTx, this provides the opportunity to perform the
abdominal dissection prior to full heparinization for CPB. Abdominal dissection prior to the implan-
tation of the lungs minimized the time that the new lungs are exposed to fluid resuscitations and
transfusion of blood products.Anesthetic management
A liver transplantationwith a newly transplanted heart or lung is challenging. The new organ is still
recovering from reperfusion. A newly transplanted heart is prone to fluid overload, arrhythmia, and
right ventricular failure. Instead of stabilizing at the intensive care unit (ICU), the new heart is sub-
jected to major stressors during subsequent liver transplantation. First, major blood loss and subse-
quent hypovolemia can accompany the dissection phase. A decrease in preload, as in inferior vena cava
clamping is not well tolerated. On the other hand, the volume overload during reperfusion can lead to
right ventricular failure. Electrolyte disturbances and acidosis associated with the anhepatic phase and
major blood loss can make the heart prone for arrhythmias. In the case of a cLiLuTx, the new lungs are
prone to suffer fluid overload if large amounts of fluids are required during liver transplant. This can
lead to pulmonary edema and a prolonged time to extubation [20]. Primary graft dysfunction can occur
shortly after pulmonary reperfusion. In patients with severe hypoxia inhaled NO is indicated. Extra-
corporeal life support (ECLS) during liver transplant is indicated in patients with severe hypoxia and/or
hypercapnia as severe hypoxia can lead to right ventricular failure and cerebral damage. Moreover,
reperfusion of the liver can lead to a sudden increase in cardiac output with high risk of pulmonary
shunting, pulmonary hypertension, and pulmonary edema.
The other way around, it is well recognized that patients with severe liver disease are at high risk for
morbidity and mortality during cardiac surgery [7,21]. Because of cirrhosis-induced coagulopathy
bleeding complications are common and avoiding the use of CPB, if possible, is advised. During cardiac
surgery, the physiology of portal hypertension is complicating hemodynamic management and
increasing the risk of major bleeding. Patients with end-stage cirrhosis are in a hyperdynamic with a
high cardiac output and a low vascular resistance requiring increased vasopressor requirements.
After the first cLiHTx in 1984, several case reports and small series have described surgical man-
agement of this complex procedure. The first report focusing on anesthetic management of a cLiHTx
was published in 2007, describing the anesthetic considerations of the intraoperative management of a
50-year-old patient with hepatitis C who developed right ventricular failure related to tricuspid valve
endocarditis [22]. Since then, reports focusing on the anesthetic management of cLiThTx are still
limited. In 2011, Eyraud M et al. describe perioperative management in 3 cLiHTx patients [23]. In those
patients, intraoperative hemodynamics were stable, with a mean transfusion need of 12 units of red
blood cells. Barbara et al. describe the intraoperative details of 27 cLiHTx patients [24]. Of those, 70%
was on inotropic support prior to surgery. Mean ± SD duration of surgery was 760 ± 125 min of which
134 ± 40min on CPB and 62 ± 11min anhepatic. In 2 patients, CPBwas used during the liver transplant.
Also, in 2 patients inhaled NO was given during liver transplant. Anesthesia was maintained with
isoflurane in all cases. Various combinations of inotropic infusions were described, most often
involving a positive inotropic and chronotropic agent.
In general, during the induction of anesthesia most patients are on standard noninvasive moni-
toring. Placing a double-lumen tube is required in case of a cLiLuTx. After induction of 2 arterial lines, a
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catheter is useful to monitor cardiac function. Transesophageal echocardiography can be used to
monitor filling status, right ventricular function, and the presence of intracardiac thrombi. Continuous
monitoring of fluid status is necessary to balance fluid management. As intraoperative coagulopathies
are complex, thromboelastography is a valuable tool to guide transfusion management.
There are no recommendations for the general anesthetic management of cLiLuTx, except some
reports addressing the mechanical circulatory support. In cLiHTx, performing the entire procedure on
CPB offers the advantage of lessening the cardiac stress (hyperkalemia, acidosis, and fluid overload)
during hepatic reperfusion. Currently, in most cases CPB is discontinued and anticoagulation is
reversed before starting the liver transplant. An alternative is the extended use of CPB with partial flow
during liver transplant providing hemodynamic or respiratory support. During CPB, full heparinization
is required. After weaning from CPB, heparin is reversed to prevent major blood loss during hepatic
dissection and the anhepatic phase. If liver transplant is performed under ECLS, anticoagulants are
required, although less than on CPB. For lung transplant, the current standard of care for mechanical
circulatory support is ECLS [25]. In 2016, Scheiermann et al. [26] describe the case of a cLiLuTx inwhich
the liver transplantation was successfully performed under ECLS instead of CPB. Venous-arterial
extracorporeal life support (vaECLS) with central cannulation was initiated prior to liver transplant
because of extensive pulmonary reperfusion edema, pulmonary hypertension, and right heart failure.
The patient was successfully weaned from ECLS on the second postoperative day. Despite extensive
transfusion requirements and a rethoracotomy, the liver and lungs functioned sufficiently. The decision
to use any form of mechanical hemodynamic support during cLiLuTx depends on the clinical status of
the patient. In patients with severe pulmonary hypertension, right heart dysfunction, hypoxia, and
hemodynamic instability could be indications.
Postoperative
The immediate postoperative care at the ICU is critical in the management of multiorgan
transplant patients. Intraoperative hemodynamic monitoring and close monitoring of the function
of the two new organs should be continued in the ICU. In the early postoperative period, high levels
of inotropic support are often described. Bleeding complications are frequent and a significant
number of the described cases require a rethoracotomy. Compared to single-organ liver trans-
plantation, the ICU length of stay is prolonged. Complications associated with liver transplantation
are primary graft failure, portal vein thrombosis, and hepatic artery thrombosis. Infectious com-
plications are frequent after lung transplantation. Specific postoperative details of a cohort of 7 CHD
(Fontan) patients after cLiHTx were described by D'Souza et al., in 2016 [27]. Median hospital length
of stay was 29 days (25e112). Acute kidney injury was the most common postoperative compli-
cation (4 out of 7 patients), with 2 patients developing chronic kidney disease without the need for
dialysis. Massive postoperative transfusion was required in 3 patients. Three patients had vocal cord
dysfunction and 2 patients required a laparotomy because of pneumoperitoneum. In the cohort of
27 cLiHTx patients described by Barbera et al., in 2015, all patients were transferred to the ICU still
intubated, ventilated, and sedated. Five of twenty-seven patients required renal replacement
therapy and none of the patients required a tracheostomy. There was only a minor transfusion
requirement with a median of 2 units of red blood cells during the first 48 h. One patient died
within 30 days because of neurological damage and multiorgan failure after surgery complicated by
major blood loss after reperfusion and an intracardiac thrombus resulting in right ventricular
failure. The immunosuppression protocol is that used for the heart or lung transplant because of the
greater tendency of rejection compared to the liver.
Outcome
The largest multicenter cohort uses the UNOS database to describe the outcome after cLiHTx. Be-
tween 1987 and 2010, 97 cLiHTx were performed in the United States [28]. Of those 97 transplants, 10
patients received a simultaneous kidney transplant and lungs were simultaneously transplanted in 11
cases. Both liver and heart graft survival were comparable to single-organ transplantation. Patient
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statistically significant, there was a trend toward a better outcome for patients with amyloidosis. In the
largest described cohorts of patients with CHD undergoing cLiHTx, survival rate is comparable to those
without CHD and to those who received a single-organ heart transplantation [9,10]. Interestingly, in
this relatively large cohort, lower rates of acute cardiac rejection were observed after simultaneous
transplantation of the liver. This phenomenon is also observed in a cohort of 40 propensity-matched
patients with CHD after cLiHTx compared to heart transplantation alone: acute rejection episodes
and treatment for rejection within the first year post transplant were significantly lower [9]. The exact
mechanism is unknown; however, the liver seems to play a key role [28]. For cLiLuTx, there is no
available evidence comparing combined transplant with lung alone. In comparison with liver alone,
cLiLuTx has comparable 1- and 5-year survival [29].
Future
 The number of patients on the waiting list for CLiThTx is increasing.
 Machine organ perfusion in the setting of combined organ liver-thoracic transplantation may
optimize the donor organ by preconditioning prior to transplantation, and allows the liver trans-
plant team a superior way of preservation of the liver during the waiting time of the thoracic organ
transplantation. Machine organ perfusion of the lungs could make it possible to change the order to
liver-first instead of lung-first in specific cases.
 Liver transplantation under mechanical hemodynamic support is indicated when the newly
transplanted heart or lungs need extra support. Possible indications are hypoxia, pulmonary edema,
pulmonary hypertension, and (right) heart failure.
 Centers performing cLiThTx should report on perioperative management and complications. The
currently available reports are limited.
Summary
CLiThTx are increasingly performed, although total numbers are still low. This increase has multiple
causes like the improved life expectancy of patients with cystic fibrosis and adults living with CHDwho
develop dual organ failure. Anesthetic management of cLiHTx and cLiLuTx transplantation is chal-
lenging. Patients have (at least) two failing organs and markedly impaired physiological reserve. Prior
to surgery, good coordination between all surgical and anesthetic teams is of utmost importance. Major
blood loss, prolonged operation time, pulmonary edema, right ventricular failure, and coagulation
disturbances are common. Despite the complexity of the procedure, outcome is equivalent to single-
organ transplant making it a feasible option for patients with coexisting organ failure. There is a
possible immunological advantage by transplanting two organs from the same donor.
Abbreviations
cLiThTx Combined liver-thoracic transplantation
cLiHTx Combined liver-heart transplantation
cLiLuTx Combined liver-lung transplantation
MELD Model for End-stage Liver Disease
SD Standard deviation
CPB cardiopulmonary bypass
ECLS Extracorporeal life support
vaECLS venous-arterial extracorporeal life support
ICU Intensive care unit
CHD Congenital Heart Disease
ESLD End-stage liver disease
CHD Congenital Heart Disease
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Practice points
 Combined transplantation of the liver and heart and/or lungs are increasingly performed;
however, the absolute number is still small.
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 There may be a protective effect against pulmonary or cardiac rejection by the simulta-
neously transplanted liver.
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